Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is enoxaparin superior to unfractionated heparin for the prevention of thromboembolism after ischemic stroke?

Nature Clinical Practice Cardiovascular Medicine volume 4, pages 528–529 (2007)Cite this article

boxed-textSherman DG et al. on behalf of the PREVAIL Investigators (2007) The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369: 1347–1355

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gregory PC and Kuhlemeier KV (2003) Prevalence of venous thromboembolism in acute hemorrhagic and thromboembolic stroke. Am J Phys Med Rehabil 82: 364–369

    PubMed  Google Scholar 

  2. Holloway RG et al. for the National Expert Stroke Panel (2001) Development of performance measures for acute ischemic stroke. Stroke 32: 2058–2074

    Article  CAS  Google Scholar 

  3. Adams HP Jr et al. (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38: 1655–1711

    Article  Google Scholar 

  4. Diener HC et al. for the PROTECT Trial Group (2006) Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT trial. Stroke 37: 139–144

    Article  CAS  Google Scholar 

  5. Hillbom M et al. (2002) Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 106: 84–92

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA harold-adams@uiowa.edu

Authors and Affiliations

  1. HP Adams Jr is Professor of Neurology and Director of the Division of Cerebrovascular Diseases at the University of Iowa Carver College of Medicine, Iowa City, IA, USA.,

    Harold P Adams Jr

Authors
  1. Harold P Adams Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

HP Adams Jr has received research support from, provided consultation to, or spoken for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Centocor, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novo Nordisk, NMT Medical, sanofi-aventis, and Wyeth. Dr Adams is also a Director of The American Board of Psychiatry and Neurology.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adams, H. Is enoxaparin superior to unfractionated heparin for the prevention of thromboembolism after ischemic stroke?. Nat Rev Cardiol 4, 528–529 (2007). https://doi.org/10.1038/ncpcardio0961

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0961

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing